DRC7

Across TCGA pan-cancer cohorts, DRC7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DRC7 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher DRC7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DRC7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

CHOL, SCLC, and HNSC are the cancer types where DRC7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
HNSC	DFS	Median	III,IV	0.050	0.611	<.001	12	view →
UCEC	DFS	Median	All	0.969	0.616	.007	10	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DRC7–CHOL (DFS)

Open the CHOL breakdown →